Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Meningitis: Researchers find possible treatment strategy without antibiotics

An illustration showing molecular reactions during meningitis.
During pneumococcal meningitis, immune cells produce structures blocking the normal cerebrospinal fluid movement. This illustration was selected as the cover image for Annals of Neurology. Illustration: Chiara Pavan & Dan Xue.

Meningitis is a very serious brain infection with limited treatment options. In a new study performed in rats, researchers from the University of Copenhagen present an alternative treatment based on immune cells that helps rinse away toxins that accumulate during the infection.

Fever, headache, confusion, seizures, amputations, or death. Meningitis is a very serious brain infection that can affect the body in many ways and needs to be treated within 24 hours of contracting the disease. The World Health Organization estimates that there are close to three million cases per year. Between the four main causes of meningitis, the WHO is particularly concerned about bacterial meningitis, which is caused by the infectious bacteria Streptococcus pneumoniae.

Despite widespread implementation of vaccines, bacterial meningitis is still associated with a high mortality rate and neurological consequences including hearing loss, focal neurological deficits, and cognitive impairment, estimated to occur in close to half of surviving patients. 

Antibiotic treatment is necessary, but with the increasing threat of antibiotic resistance, there is a growing need for new treatment strategies. 

Now, in a new study performed in rats, researchers from the University of Copenhagen and Lund University were able to utilize the body’s own immune cells to kill the bacterial meningitis infection.

“In a rat model, we observed that the neutrophils, a type of immune cells, form a net-like structure in the brain’s membrane, the meninges. But this particular net-structure also causes brain swelling and prevents the removal of waste products. We discovered, that if we dissolved the structure – not the immune cells – the immune cells still kill the meningitis bacteria but without causing brain swelling,” says Ph.D. Chiara Pavan, first author of the study.

Meningitis

According to the World Health Organization, meningitis remains a major global public-health challenge. Many organisms can cause meningitis including bacteria, viruses, fungi and parasites. There are four main causes of meningitis.

  • Neisseria meningitidis (meningococcus) 
  • Streptococcus pneumoniae (pneumococcus) 
  • Haemophilus influenzae 
  • Streptococcus agalactiae (group B streptococcus)

Bacterial meningitis is of particular concern, killing 1 in 10 and leaving 1 in 5 with serious complications.

Source: WHO

Immune cells block the movement of brain fluid

The researchers show that immune cells entering the brain’s membrane, create a net that traps bacteria but also blocks the movement of cerebrospinal fluid. The brain is constantly cleaned by the cerebrospinal fluid that enters the tissue along blood vessels and is responsible for clearing out waste products made by the active brain cells.

This fluid transport system was named the glymphatic system by Maiken Nedergaard, and its function has been shown to be critical for avoiding the accumulation of protein plaques that accumulate in patients with Alzheimer's disease. Glymphatic transport of cerebrospinal fluid is also important for avoiding brain swelling in acute diseases such as stroke.

Brain swelling, also called edema, is a life-threatening condition because the brain is contained within the skull. The swelling compresses blood vessels resulting in loss of brain tissue, which is fatal when the brain regions that control breathing stop working.

That brain swelling in meningitis is caused by blockage of the glymphatic system is now shown for the first time in collaboration between Maiken Nedergaards group at the University of Copenhagen and Iben Lundgaard at MultiPark at Lund University.

“When the immune cells enter the brain, they eat the bacteria, but while doing so the immune cells also produce inflammatory components, including nets that cause swelling,” the research team says.

“The most important aspects of our study is that it suggests that meningitis can be treated by administration of an enzyme that degrades the neutrophil nets. Enzymatic removal of nets eliminated the often fatal accumulation of fluid in the brain in rats with bacterial meningitis. This novel treatment can be combined with antibiotics if needed,” explains Iben Lundgaard.

Hope for an international clinical study

The researchers theorized that if the nets were dissolved, leaving just the immune cells without their nets in the meninges, it would allow the cerebrospinal fluid to pass the brain freely.

The net-like structures consist mainly of DNA, so the research team applied drugs for cutting up DNA, so-called DNase. They gave DNase to the rats infected with pneumococcus bacteria, which causes bacterial meningitis.

“We administered DNase to rats infected with the bacteria, and we were able to show that the nets dissolved. The treatment reduced brain swelling and helped in removing metabolic waste production from the infected brain. In contrast, antibiotic treatment did not have an effect on brain swelling or waste clearance,” says Maiken Nedergaard.

Based on their results, the research team now hopes to set up an international clinical study to investigate DNase in the treatment of patients with bacterial meningitis. Antibiotic resistance is increasing at an alarming rate and the drug the researchers use here is a promising alternative, and has already been approved for human use in other neurological diseases. 

“We would also like to investigate how metabolic waste products removal is impaired in other diseases of the brain such as multiple sclerosis or viral meningitis,” says Iben Lundgaard.

This news article was originally published at the Faculty of Health and Medical Sciences, University of Copenhagen.

Read the full paper ‘DNase Treatment Prevents Cerebrospinal Fluid Block in Early Experimental Pneumococcal Meningitis’. 

Profile photo of Iben Lundgaard.
Photo:Tekla Kylkilahti

Iben Lundgaard

Associate Professor

iben [dot] lundgaard [at] med [dot] lu [dot] se

Link to Iben Lundgaard's profile in the LU Research Portal

Twitter: @Iben_Lundgaard

Profile photo of Chiara Pavan.

Chiara Pavan

Ph.D. student at Faculty of Health and Medical Sciences
University of Copenhagen 

chiara [dot] sdn [at] hotmail [dot] it